A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Locally Advanced Breast Cancer|Breast Cancer
Interventions: DRUG: Samuraciclib|DRUG: Elacestrant Dihydrochloride
Sponsor: Carrick Therapeutics Limited
Collaborators: Berlin-Chemie AG Menarini Group